Identification

Name
Betamethasone
Accession Number
DB00443  (APRD00513)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)

Structure
Thumb
Synonyms
  • 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
  • 16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
  • 9-Fluoro-16beta-methylprednisolone
  • 9-Fluoro-16β-methylprednisolone
  • 9alpha-Fluoro-16beta-methylprednisolone
  • 9α-Fluoro-16β-methylprednisolone
  • beta-Methasone alcohol
  • Betadexamethasone
  • Betametasona
  • Betamethasone
  • Betamethasonum
  • Betamethasonvalerat Mikron
  • Rinderon
External IDs
NSC-39470 / SCH 4831 / SCH-4831
Product Ingredients
IngredientUNIICASInChI Key
Betamethasone acetateTI05AO53L7987-24-6AKUJBENLRBOFTD-QZIXMDIESA-N
Betamethasone benzoate877K0XW47A22298-29-9SOQJPQZCPBDOMF-YCUXZELOSA-N
Betamethasone dihydrogen phosphateYJO1F9W10R360-63-4VQODGRNSFPNSQE-DVTGEIKXSA-N
Betamethasone dipropionate826Y60901U5593-20-4CIWBQSYVNNPZIQ-XYWKZLDCSA-N
Betamethasone sodium phosphate7BK02SCL3W151-73-5PLCQGRYPOISRTQ-LWCNAHDDSA-L
Betamethasone valerate9IFA5XM7R22152-44-5SNHRLVCMMWUAJD-SUYDQAKGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Beben Gel 0.025%Gel0.025 %TopicalParke Davis Division, Warner Lambert Canada Inc.1973-12-311999-04-08Canada
Betacort Scalp Lotion 0.1%Liquid.1 %TopicalIcn Pharmaceuticals1981-12-312005-04-26Canada
Betaderm Crm 0.05%Cream0.05 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Crm 0.1%Cream0.1 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Lotion 0.1%Lotion0.1 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Ont 0.05%Ointment0.05 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Ont 0.1%Ointment0.1 %TopicalTaro Pharmaceuticals, Inc.1988-12-31Not applicableCanada
Betagel - 0.1%Gel.1 %TopicalUcb Inc1996-12-061998-04-21Canada
Betamethasone DipropionateCream.5 mg/gTopicalA S Medication Solutions1984-06-262017-06-20Us
Betamethasone DipropionateOintment.5 mg/gTopicalPreferreed Pharmaceuticals Inc.2017-04-17Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetamethasoneCream.5 mg/gTopicalImpax Generics2004-01-232017-10-17Us
Betamethasone DipropionateCream.5 mg/gTopicalPhysicians Total Care, Inc.1994-12-15Not applicableUs
Betamethasone DipropionateCream, augmented.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2003-12-09Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalNu Care Pharmaceuticals,inc.2008-09-23Not applicableUs
Betamethasone DipropionateGel.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2003-05-13Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalA S Medication Solutions2002-09-032017-06-20Us
Betamethasone DipropionateOintment, augmented.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2004-10-12Not applicableUs
Betamethasone DipropionateGel.64 mg/gTopicalPhysicians Total Care, Inc.2006-10-17Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalActavis Pharma Company2002-09-03Not applicableUs
Betamethasone DipropionateLotion, augmented.5 mg/mLTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2007-05-21Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betamethasone SP 24mg/2mL PFInjection, solution12 mg/mLEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-12-29Us
Dr. Throwers BetaCream.05 g/100gTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
Dr. Throwers BetaOintment.05 g/100gTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
International/Other Brands
Bentelan (Defiante) / Betnovate (GlaxoSmithKline) / Celestamine (Schering-Plough) / Celestone (Schering-Plough) / Diprosone (Schering-Plough) / Fucibet (LEO) / Procort / Rinderon (Shionogi Seiyaku)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BetajectBetamethasone (3 mg) + Betamethasone acetate (3 mg)SuspensionIntra-articular; Intralesional; IntramuscularSandoz Canada Incorporated1998-07-02Not applicableCanada
BetajectBetamethasone (3 mg) + Betamethasone acetate (3 mg)SuspensionIntra-articular; Intralesional; IntramuscularSandoz Canada Incorporated1998-07-02Not applicableCanada
Betaloan SUIKBetamethasone sodium phosphate (3 mg/mL) + Betamethasone acetate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAsclemed Usa, Inc.2010-04-28Not applicableUs
Betaloan SUIKBetamethasone sodium phosphate (3 mg/mL) + Betamethasone acetate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAsclemed Usa, Inc.2010-04-28Not applicableUs
Betamethasone ClotrimazoleBetamethasone dipropionate (.64 mg/1) + Clotrimazole (10 mg/1)CreamTopicalStat Rx USA2002-08-02Not applicableUs
Betamethasone Combo 6mg/mL PFBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Combo 6mg/mL PFBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Combo 7mg/mLBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (4 mg/mL)Injection, suspensionIntramuscularUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Combo 7mg/mLBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (4 mg/mL)Injection, suspensionIntramuscularUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAmerican Regent2010-04-28Not applicableUs
Categories
UNII
9842X06Q6M
CAS number
378-44-9
Weight
Average: 392.4611
Monoisotopic: 392.199902243
Chemical Formula
C22H29FO5
InChI Key
UREBDLICKHMUKA-DVTGEIKXSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.

Structured Indications
Pharmacodynamics

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.

Mechanism of action

Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Minimal if applied topically.

Volume of distribution
Not Available
Protein binding

64%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

5.6 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Betamethasone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Betamethasone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Betamethasone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Betamethasone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Betamethasone.Approved
AcetaminophenThe serum concentration of Betamethasone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Betamethasone.Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betamethasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Betamethasone.Approved
AfatinibThe serum concentration of Betamethasone can be increased when it is combined with Afatinib.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Betamethasone.Experimental
AlbendazoleThe serum concentration of Betamethasone can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Betamethasone.Approved, Withdrawn
AldesleukinBetamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneThe serum concentration of Betamethasone can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Betamethasone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Betamethasone can be increased when it is combined with Alfentanil.Approved, Illicit
AlgeldrateThe bioavailability of Betamethasone can be decreased when combined with Algeldrate.Experimental
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Betamethasone.Investigational
AlmagateThe bioavailability of Betamethasone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Betamethasone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Betamethasone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Betamethasone.Approved
AloglutamolThe bioavailability of Betamethasone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Betamethasone.Experimental
AluminiumThe bioavailability of Betamethasone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Betamethasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Betamethasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Betamethasone can be decreased when combined with Aluminum hydroxide.Approved
AmantadineThe serum concentration of Betamethasone can be increased when it is combined with Amantadine.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ambenonium.Approved
Aminohippuric acidThe serum concentration of Betamethasone can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Betamethasone.Approved
AmiodaroneThe serum concentration of Betamethasone can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Betamethasone can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Betamethasone can be increased when it is combined with Amlodipine.Approved
Amphotericin BBetamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Betamethasone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Betamethasone can be increased when it is combined with Amsacrine.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Betamethasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Betamethasone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betamethasone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Betamethasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Betamethasone.Approved, Investigational
AprepitantThe serum concentration of Betamethasone can be increased when it is combined with Aprepitant.Approved, Investigational
AstemizoleThe serum concentration of Betamethasone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Betamethasone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Betamethasone can be increased when it is combined with Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Betamethasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Betamethasone.Withdrawn
AzelastineThe serum concentration of Betamethasone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Betamethasone can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Betamethasone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Betamethasone.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Betamethasone.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Betamethasone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Betamethasone.Experimental
BendroflumethiazideBetamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Betamethasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Betamethasone.Withdrawn
BenzocaineThe serum concentration of Betamethasone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Betamethasone.Approved
BepridilThe serum concentration of Betamethasone can be increased when it is combined with Bepridil.Approved, Withdrawn
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Betamethasone.Experimental
BiperidenThe serum concentration of Betamethasone can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe bioavailability of Betamethasone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Betamethasone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Betamethasone can be increased when it is combined with Boceprevir.Withdrawn
BosutinibThe serum concentration of Betamethasone can be increased when it is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Betamethasone.Approved
BromocriptineThe serum concentration of Betamethasone can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Betamethasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Betamethasone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Betamethasone.Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Betamethasone.Experimental
BumetanideBetamethasone may increase the hypokalemic activities of Bumetanide.Approved
BuprenorphineThe serum concentration of Betamethasone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Betamethasone can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Betamethasone can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Betamethasone.Approved
CaffeineThe serum concentration of Betamethasone can be increased when it is combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Betamethasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Betamethasone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Betamethasone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe serum concentration of Betamethasone can be increased when it is combined with Canagliflozin.Approved
Candesartan cilexetilThe serum concentration of Betamethasone can be increased when it is combined with Candesartan.Approved
Capromab pendetideBetamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Betamethasone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Betamethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Betamethasone.Experimental
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Betamethasone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Betamethasone.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Betamethasone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Betamethasone can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Betamethasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Betamethasone.Approved, Investigational
CeritinibBetamethasone may increase the hyperglycemic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Betamethasone.Withdrawn
ChloroquineThe serum concentration of Betamethasone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideBetamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Betamethasone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Betamethasone can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Betamethasone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Betamethasone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneBetamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Betamethasone can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Betamethasone can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Betamethasone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Betamethasone.Experimental
CilazaprilThe serum concentration of Betamethasone can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Betamethasone can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe serum concentration of Betamethasone can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Betamethasone can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Betamethasone can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Betamethasone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Betamethasone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Betamethasone.Approved
ClotrimazoleThe serum concentration of Betamethasone can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Betamethasone can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Betamethasone can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Betamethasone can be increased when it is combined with Colforsin.Experimental
Conjugated estrogensThe serum concentration of Betamethasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Betamethasone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Betamethasone is combined with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Betamethasone can be increased when it is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Betamethasone.Investigational
CyclopenthiazideBetamethasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe serum concentration of Betamethasone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Betamethasone can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Betamethasone.Investigational
DaclatasvirThe serum concentration of Betamethasone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Betamethasone can be increased when it is combined with Dactinomycin.Approved
DaidzeinThe serum concentration of Betamethasone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Betamethasone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Betamethasone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Betamethasone can be decreased when it is combined with Daunorubicin.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Betamethasone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Betamethasone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Betamethasone.Investigational
DesipramineThe serum concentration of Betamethasone can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Betamethasone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Betamethasone can be increased when it is combined with Dextromethorphan.Approved
DichlorvosThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dichlorvos.Vet Approved
DiclofenacThe serum concentration of Betamethasone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Betamethasone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Betamethasone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Betamethasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betamethasone.Approved
DigoxinThe serum concentration of Betamethasone can be decreased when it is combined with Digoxin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Betamethasone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Betamethasone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Betamethasone.Experimental
DihydroergotamineThe serum concentration of Betamethasone can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneBetamethasone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe serum concentration of Betamethasone can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Betamethasone can be increased when it is combined with Dipyridamole.Approved
DistigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Betamethasone is combined with Donepezil.Approved
DoxazosinThe serum concentration of Betamethasone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Betamethasone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Betamethasone can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Betamethasone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Betamethasone can be increased when it is combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Betamethasone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Betamethasone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Betamethasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Betamethasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Edrophonium.Approved
ElbasvirThe serum concentration of Betamethasone can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Betamethasone.Approved
EnalaprilThe serum concentration of Betamethasone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Betamethasone can be increased when it is combined with Enasidenib.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Betamethasone can be increased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Betamethasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Betamethasone.Approved
EquolThe serum concentration of Betamethasone can be increased when it is combined with Equol.Investigational
ErgonovineThe serum concentration of Betamethasone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Betamethasone can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Betamethasone can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Betamethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Betamethasone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Betamethasone can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Betamethasone can be decreased when it is combined with Estrone.Approved
Etacrynic acidBetamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Betamethasone.Experimental
Ethinyl EstradiolThe serum concentration of Betamethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Betamethasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Betamethasone.Approved
EtoposideThe serum concentration of Betamethasone can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Betamethasone.Approved, Investigational
EtravirineThe serum concentration of Betamethasone can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Betamethasone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Betamethasone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Betamethasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Betamethasone.Experimental
FelodipineThe serum concentration of Betamethasone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Betamethasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Betamethasone.Approved
FentanylThe serum concentration of Betamethasone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Betamethasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Betamethasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Betamethasone.Experimental
FexofenadineThe serum concentration of Betamethasone can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Betamethasone can be increased when it is combined with Fidaxomicin.Approved
FingolimodBetamethasone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Betamethasone.Approved, Withdrawn
FluconazoleThe serum concentration of Betamethasone can be increased when it is combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Betamethasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Betamethasone.Experimental
FluoxetineThe serum concentration of Betamethasone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneBetamethasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Betamethasone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Betamethasone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Betamethasone can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Betamethasone.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Betamethasone.Approved
FluvoxamineThe serum concentration of Betamethasone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosaprepitantThe serum concentration of Betamethasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Betamethasone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideBetamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
GalantamineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Betamethasone can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Betamethasone can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ginkgo biloba.Approved, Nutraceutical
GlecaprevirThe serum concentration of Betamethasone can be increased when it is combined with Glecaprevir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Betamethasone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Betamethasone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Betamethasone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Betamethasone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Betamethasone.Approved
GLPG-0492Betamethasone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe serum concentration of Betamethasone can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Betamethasone can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Betamethasone.Approved
Gramicidin DThe serum concentration of Betamethasone can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Betamethasone can be increased when it is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Betamethasone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Betamethasone.Investigational
HaloperidolThe serum concentration of Betamethasone can be increased when it is combined with Haloperidol.Approved
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Betamethasone.Experimental
HexestrolThe serum concentration of Betamethasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Betamethasone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Betamethasone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.Approved, Investigational
HydrochlorothiazideBetamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Betamethasone can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideBetamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Betamethasone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Betamethasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Betamethasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Betamethasone.Approved
IdelalisibThe serum concentration of Betamethasone can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Betamethasone can be increased when it is combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Betamethasone.Experimental
ImipramineThe serum concentration of Betamethasone can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Betamethasone.Approved
IndapamideBetamethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Betamethasone can be decreased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Betamethasone.Investigational
IndomethacinThe serum concentration of Betamethasone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Betamethasone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Betamethasone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Betamethasone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Betamethasone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Betamethasone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Betamethasone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Betamethasone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Betamethasone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ipidacrine.Experimental
IsavuconazoniumThe serum concentration of Betamethasone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Betamethasone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Betamethasone.Withdrawn
ItraconazoleThe serum concentration of Betamethasone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Betamethasone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Betamethasone can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Betamethasone.Experimental
KetamineThe serum concentration of Betamethasone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Betamethasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Betamethasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Betamethasone.Approved
LansoprazoleThe serum concentration of Betamethasone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Betamethasone can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Betamethasone can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Betamethasone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Betamethasone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Betamethasone.Approved
LiothyronineThe serum concentration of Betamethasone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Betamethasone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Betamethasone.Approved
LisinoprilThe serum concentration of Betamethasone can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Betamethasone.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Betamethasone.Approved
LomitapideThe serum concentration of Betamethasone can be increased when it is combined with Lomitapide.Approved
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Betamethasone.Experimental
LoperamideThe serum concentration of Betamethasone can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Betamethasone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Betamethasone can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Betamethasone.Approved
LosartanThe serum concentration of Betamethasone can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Betamethasone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Betamethasone.Approved
LumacaftorThe serum concentration of Betamethasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Betamethasone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Betamethasone.Illicit, Withdrawn
MagaldrateThe bioavailability of Betamethasone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Betamethasone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Betamethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Betamethasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betamethasone.Approved
Magnesium silicateThe bioavailability of Betamethasone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Betamethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Betamethasone is combined with Malathion.Approved, Investigational
MaprotilineThe serum concentration of Betamethasone can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Betamethasone.Approved
MebendazoleThe serum concentration of Betamethasone can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Betamethasone.Approved
MefloquineThe serum concentration of Betamethasone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Betamethasone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Betamethasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Memantine.Approved, Investigational
MeprobamateThe serum concentration of Betamethasone can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Betamethasone.Approved
MesteroloneBetamethasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Betamethasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Betamethasone.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Betamethasone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.Approved
MethadoneThe serum concentration of Betamethasone can be increased when it is combined with Methadone.Approved
MethallenestrilThe serum concentration of Betamethasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideBetamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Methyl salicylate.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Betamethasone.Approved
MethyltestosteroneBetamethasone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Betamethasone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Metoclopramide.Approved, Investigational
MetolazoneBetamethasone may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Betamethasone can be increased when it is combined with Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Betamethasone.Experimental
MibefradilThe serum concentration of Betamethasone can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Betamethasone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Betamethasone can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Betamethasone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Betamethasone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Betamethasone.Approved, Investigational
MitomycinThe serum concentration of Betamethasone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Betamethasone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Betamethasone can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the adverse neuromuscular activities of Betamethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Betamethasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Betamethasone.Experimental
MorphineThe serum concentration of Betamethasone can be increased when it is combined with Morphine.Approved, Investigational
MoxestrolThe serum concentration of Betamethasone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betamethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betamethasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Betamethasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Betamethasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Betamethasone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NandroloneBetamethasone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Betamethasone.Approved, Vet Approved
NaringeninThe serum concentration of Betamethasone can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Betamethasone.Approved, Investigational
NefazodoneThe serum concentration of Betamethasone can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Betamethasone can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nemonoxacin.Investigational
NeostigmineThe serum concentration of Betamethasone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Betamethasone.Approved
NevirapineThe serum concentration of Betamethasone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Betamethasone can be increased when it is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Betamethasone.Approved
NicorandilThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nicorandil.Approved
NifedipineThe serum concentration of Betamethasone can be decreased when it is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Betamethasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Betamethasone.Approved
NilotinibThe serum concentration of Betamethasone can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Betamethasone.Approved, Withdrawn
NisoldipineThe serum concentration of Betamethasone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Betamethasone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Betamethasone can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Betamethasone.Investigational
NorethisteroneThe serum concentration of Betamethasone can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betamethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Betamethasone.Approved
OmeprazoleThe serum concentration of Betamethasone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Betamethasone.Vet Approved
OxandroloneBetamethasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Betamethasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Oxolinic acid.Experimental
OxymetholoneBetamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betamethasone.Withdrawn
P-NitrophenolThe serum concentration of Betamethasone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Betamethasone can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Betamethasone can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Betamethasone can be increased when it is combined with Pantoprazole.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Betamethasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Betamethasone.Approved
ParoxetineThe serum concentration of Betamethasone can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Betamethasone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Betamethasone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Betamethasone.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Betamethasone can be increased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Betamethasone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Betamethasone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Betamethasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Betamethasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Betamethasone.Approved, Investigational
PhenytoinThe serum concentration of Betamethasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Physostigmine.Approved
PibrentasvirThe serum concentration of Betamethasone can be increased when it is combined with Pibrentasvir.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.Approved, Investigational
PimozideThe serum concentration of Betamethasone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Betamethasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pipemidic acid.Experimental
PiretanideBetamethasone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Betamethasone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betamethasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Betamethasone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Betamethasone.Approved
Platelet Activating FactorThe serum concentration of Betamethasone can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphateThe serum concentration of Betamethasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideBetamethasone may increase the hypokalemic activities of Polythiazide.Approved
PonatinibThe serum concentration of Betamethasone can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Betamethasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Betamethasone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Betamethasone.Experimental
PravastatinThe serum concentration of Betamethasone can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Betamethasone can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Betamethasone can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Betamethasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Betamethasone can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Betamethasone can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Betamethasone.Experimental
PromestrieneThe serum concentration of Betamethasone can be increased when it is combined with Promestriene.Investigational
PromethazineThe serum concentration of Betamethasone can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Betamethasone.Approved
PropafenoneThe serum concentration of Betamethasone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Betamethasone can be increased when it is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Betamethasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Betamethasone.Experimental
ProtriptylineThe serum concentration of Betamethasone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Betamethasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pyridostigmine.Approved
QuercetinThe serum concentration of Betamethasone can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Betamethasone can be increased when it is combined with Quinacrine.Approved
QuinestrolThe serum concentration of Betamethasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneBetamethasone may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe serum concentration of Betamethasone can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Betamethasone can be increased when it is combined with Quinine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Betamethasone.Approved
RanitidineThe serum concentration of Betamethasone can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Betamethasone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Betamethasone.Withdrawn
ReboxetineThe serum concentration of Betamethasone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Betamethasone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Betamethasone.Approved, Investigational
ReserpineThe serum concentration of Betamethasone can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone.Experimental, Investigational
RifabutinThe serum concentration of Betamethasone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Betamethasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Betamethasone can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Betamethasone can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Betamethasone can be decreased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Betamethasone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Betamethasone.Approved
RolapitantThe serum concentration of Betamethasone can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Betamethasone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Betamethasone.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Betamethasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Betamethasone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Betamethasone.Approved
SaquinavirThe serum concentration of Betamethasone can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Betamethasone.Approved
ScopolamineThe serum concentration of Betamethasone can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolThe serum concentration of Betamethasone can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Betamethasone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Betamethasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Betamethasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Betamethasone.Investigational
SertralineThe serum concentration of Betamethasone can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Betamethasone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Betamethasone can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Betamethasone.Approved
SirolimusThe serum concentration of Betamethasone can be decreased when it is combined with Sirolimus.Approved, Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sitafloxacin.Experimental
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Betamethasone.Approved, Investigational
SorafenibThe serum concentration of Betamethasone can be increased when it is combined with Sorafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Betamethasone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sparfloxacin.Approved
SpironolactoneThe serum concentration of Betamethasone can be increased when it is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Betamethasone.Investigational
St. John's WortThe serum concentration of Betamethasone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololBetamethasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Betamethasone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Betamethasone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Betamethasone can be decreased when it is combined with Streptozocin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Betamethasone.Approved
SulfinpyrazoneThe serum concentration of Betamethasone can be increased when it is combined with Sulfinpyrazone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Betamethasone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Betamethasone.Approved, Investigational
SumatriptanThe serum concentration of Betamethasone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Betamethasone can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Betamethasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Betamethasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Betamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Betamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe serum concentration of Betamethasone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Betamethasone.Approved, Investigational
TamoxifenThe serum concentration of Betamethasone can be decreased when it is combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Betamethasone.Investigational
Taurocholic AcidThe serum concentration of Betamethasone can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Betamethasone.Withdrawn
TelithromycinThe serum concentration of Betamethasone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Betamethasone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Temafloxacin.Withdrawn
TemsirolimusThe serum concentration of Betamethasone can be increased when it is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Betamethasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Betamethasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Betamethasone.Vet Approved
TerazosinThe serum concentration of Betamethasone can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Betamethasone can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Betamethasone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Betamethasone.Approved
TesmilifeneThe serum concentration of Betamethasone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Betamethasone can be increased when it is combined with Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Betamethasone.Approved
TiboloneThe serum concentration of Betamethasone can be increased when it is combined with Tibolone.Approved
TicagrelorThe serum concentration of Betamethasone can be increased when it is combined with Ticagrelor.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Betamethasone.Investigational
TofacitinibBetamethasone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Betamethasone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Betamethasone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Betamethasone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Betamethasone.Approved
TolvaptanThe serum concentration of Betamethasone can be increased when it is combined with Tolvaptan.Approved
TorasemideBetamethasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Betamethasone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Betamethasone.Approved, Investigational
TrazodoneThe serum concentration of Betamethasone can be decreased when it is combined with Trazodone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Betamethasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Betamethasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideBetamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Betamethasone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Betamethasone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Betamethasone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Betamethasone can be increased when it is combined with Trimipramine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Betamethasone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Betamethasone.Withdrawn
TroleandomycinThe serum concentration of Betamethasone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Betamethasone.Experimental
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Betamethasone.Investigational, Withdrawn
VelpatasvirThe serum concentration of Betamethasone can be increased when it is combined with Velpatasvir.Approved
VenlafaxineThe serum concentration of Betamethasone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Betamethasone can be decreased when it is combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Betamethasone.Approved, Investigational
VinblastineThe serum concentration of Betamethasone can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Betamethasone can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Betamethasone can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Betamethasone.Approved, Investigational
VoriconazoleThe serum concentration of Betamethasone can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Betamethasone can be increased when it is combined with Voxilaprevir.Approved
WarfarinBetamethasone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Betamethasone.Approved
ZeranolThe serum concentration of Betamethasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Betamethasone.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Betamethasone can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Betamethasone.Withdrawn
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Fernando AHUMADA AYALA, "SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE." U.S. Patent US20100063015, issued March 11, 2010.

US20100063015
General References
Not Available
External Links
Human Metabolome Database
HMDB14586
KEGG Drug
D00244
PubChem Compound
9782
PubChem Substance
46505155
ChemSpider
9399
BindingDB
73823
ChEBI
3077
ChEMBL
CHEMBL632
Therapeutic Targets Database
DAP001043
PharmGKB
PA164754818
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Betamethasone
ATC Codes
S01BB04 — Betamethasone and mydriaticsR03BA04 — BetamethasoneS01CA05 — Betamethasone and antiinfectivesH02AB01 — BetamethasoneR01AD06 — BetamethasoneD07CC01 — Betamethasone and antibioticsD07BC01 — Betamethasone and antisepticsC05AA05 — BetamethasoneD07AC01 — BetamethasoneA07EA04 — BetamethasoneD07XC01 — BetamethasoneS03BA03 — BetamethasoneS01CB04 — BetamethasoneS02BA07 — BetamethasoneS01BA06 — BetamethasoneS03CA06 — Betamethasone and antiinfectives
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 56:36.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (37.5 KB)
MSDS
Download (71.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePsoriasis Vulgaris1
1CompletedOtherPsoriasis1
1CompletedOtherPsoriasis Vulgaris1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentPlaque Type Psoriasis1
1CompletedTreatmentPsoriasis3
1CompletedTreatmentPsoriasis Vulgaris1
1RecruitingTreatmentBotulinum Toxins, Type A / Plantar Fascitis1
1RecruitingTreatmentScalp Psoriasis1
1, 2CompletedTreatmentArthritis / Psoriasis1
1, 2CompletedTreatmentPsoriasis2
1, 2TerminatedPreventionCongenital Cystic Adenomatoid Malformation (CCAM)1
1, 2Unknown StatusTreatmentCorneal Diseases / Hypermetropia / Myopia / Pterygium1
2CompletedPreventionLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Colorectal Cancers1
2CompletedTreatmentHip Pain Etiology Unknown1
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2CompletedTreatmentOral Lichen Planus / Recurrent Aphthous Stomatitis1
2CompletedTreatmentPruritus in Patients With Atopic Dermatitis1
2CompletedTreatmentPsoriasis Vulgaris2
2Not Yet RecruitingTreatmentAchilles Tendinitis / Lateral Epicondylitis / Rotator Cuff Syndrome1
2Not Yet RecruitingTreatmentLateral Epicondylitis / Rotator Cuff Syndrome1
2RecruitingTreatmentInjuries, Ankle1
2RecruitingTreatmentOral Lichen Planus1
2Unknown StatusPreventionRespiratory Distress Syndrome, Newborn / Transient Tachypnea of the Newborn1
2Unknown StatusTreatmentLate Preterm1
2, 3Not Yet RecruitingTreatmentPPROM / Respiratory Distress Syndrome In Premature Infants1
2, 3TerminatedPreventionRespiratory Distress Syndrome, Newborn1
2, 3TerminatedTreatmentBronchiolitis / Children1
3CompletedPreventionPostoperative Emesis / Prophylaxis against postoperative nausea and vomiting1
3CompletedPreventionPregnancy / Pregnancy Outcomes / Respiratory Distress1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
3CompletedTreatmentCoughing / Throat Pain1
3CompletedTreatmentDermatitis, Eczematous1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentPsoriasis Vulgaris3
3CompletedTreatmentRespiratory Distress Syndrome (RDS)1
3RecruitingTreatmentNeonatal Complications1
3TerminatedTreatmentComplications, Pregnancy1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentOral Lichen Planus1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentAtopic Dermatitis (AD) / Dermatitis, Contact / Psoriasis / Seborrheic Dermatitis1
3WithdrawnTreatmentPremature Births / Premature Labour1
4CompletedPreventionHand Eczema1
4CompletedPreventionNeonatal Distress1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentBack Pain / Cervical Pain1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPsoriasis Vulgaris1
4CompletedTreatmentRhinitis1
4CompletedTreatmentSynovitis of osteoarthritis1
4Not Yet RecruitingPreventionChronic Migraine1
4Not Yet RecruitingTreatmentBack Pain With Radiation / Low Back Pain (LBP) / Radicular; Neuropathic, Lumbar, Lumbosacral1
4Not Yet RecruitingTreatmentTrigger Finger1
4RecruitingPreventionNeonatal Respiratory Distress1
4RecruitingTreatmentDeQuervain Tendinopathy1
4RecruitingTreatmentDeQuervain's Tenosynovitis1
4RecruitingTreatmentOsteoarthritis of the Knees1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPlaque Psoriasis1
4RecruitingTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentAtopic Dermatitis (AD) / Skin Diseases, Eczematous1
4TerminatedTreatmentPlaque Psoriasis1
4WithdrawnTreatmentPhimosis1
Not AvailableCompletedNot AvailablePlaque Psoriasis2
Not AvailableCompletedPreventionHyaline Membrane Disease / Transient Tachypnea1
Not AvailableCompletedTreatmentBack Pain / Cervical Pain1
Not AvailableCompletedTreatmentDiscoid Lupus Erythematosus (DLE)1
Not AvailableCompletedTreatmentIntraventricular Hemorrhage / Neonatal Mortality / Respiratory Distress Syndrome (RDS)1
Not AvailableCompletedTreatmentPsoriasis1
Not AvailableRecruitingNot AvailablePsoriasis Vulgaris1
Not AvailableTerminatedTreatmentThumb Carpometacarpal Joint Osteoarthritis1
Not AvailableUnknown StatusPreventionFunctional Residual Capacity / Pulmonary Function Testing / Respiratory Compliance1
Not AvailableUnknown StatusTreatmentAutoimmune Diseases / Chronic Hepatitis C Infection / Lichen Planus (LP) / Vasculitis1
Not AvailableUnknown StatusTreatmentChronic Plantar Fasciitis1
Not AvailableUnknown StatusTreatmentPolymyalgia Rheumatica1
Not AvailableWithdrawnTreatmentBursitis / Tendonitis1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Parke davis div warner lambert co
  • Parke davis pharmaceutical research div warner lambert co
  • Altana inc
  • Glenmark generics inc usa
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Tolmar inc
  • Schering corp
  • Savage laboratories inc div altana inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Teva pharmaceuticals usa inc
  • Alpharma us pharmaceuticals division
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Connectics corp
  • Tj roaco ltd
  • Pharmafair inc
  • Stat trade inc
Packagers
Dosage forms
FormRouteStrength
GelTopical0.025 %
LiquidTopical.1 %
GelTopical.1 %
SuspensionIntra-articular; Intralesional; Intramuscular
Injection, suspensionIntra-articular; Intralesional; Intramuscular
CreamTopical
Injection, suspensionEpidural; Intramuscular; Intraspinal; Intrathecal
Injection, suspensionIntramuscular
CreamTopical.5 mg/g
CreamTopical.64 mg/g
Cream, augmentedTopical.5 mg/g
GelTopical.5 mg/g
GelTopical.64 mg/g
LotionTopical.5 mg/g
Lotion, augmentedTopical.5 mg/mL
OintmentTopical.05 mg/g
OintmentTopical.5 mg/g
Ointment, augmentedTopical.5 mg/g
LotionTopical.64 mg/mL
Injection, solutionEpidural; Intramuscular; Intraspinal; Intrathecal12 mg/mL
CreamTopical1 mg/g
CreamTopical1.2 mg/g
LotionCutaneous1 mg/mL
LotionTopical1 mg/mL
OintmentTopical1 mg/g
OintmentTopical1.2 mg/g
LotionTopical1.22 mg
CreamTopical.05 %
CreamTopical.64 mg
LotionTopical.64 mg
OintmentTopical.64 mg
PatchTopical0.1 %
Solution / dropsAuricular (otic); Ophthalmic.1 %
LiquidAuricular (otic); Ophthalmic0.1 %
TabletTopical0.1 mg
EnemaRectal5 mg
TabletOral.5 mg
Tablet, effervescentOral0.5 mg
CreamTopical.1 %
LotionTopical.1 %
OintmentTopical.1 %
OintmentTopical0.1 %
OintmentTopical0.05 %
Tablet, extended releaseOral1 mg
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Soft tissue
SuspensionIntra-articular; Intrabursal; Intradermal; Intramuscular
TabletOral0.5 mg
LotionTopical
Kit
LotionTopical.5 mg/mL
LiquidAuricular (otic); Ophthalmic
GelTopical
CreamTopical.05 g/100g
OintmentTopical.05 g/100g
Aerosol, foamTopical
SolutionAuricular (otic); Ophthalmic
OintmentOphthalmic
Aerosol, foamTopical0.12 %
Aerosol, foamTopical1.2 mg/g
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Topical
LotionTopical.05 %
CreamTopical0.05 %
LotionTopical0.05 %
CreamTopical0.1 %
CreamTopical0.5 mg
LotionTopical.5 mg
OintmentTopical.5 mg
CreamTopical.5 mg
OintmentTopical.05 %
SprayTopical.5 mg/g
OintmentTopical
Spray, meteredTopical
SuspensionTopical
LotionTopical0.1 %
Prices
Unit descriptionCostUnit
Luxiq 0.12% Foam 100 gm Can325.17USD can
Luxiq 0.12% Foam 50 gm Can174.7USD can
Diprolene 0.05% Lotion 60ml Bottle148.19USD bottle
Diprolene 0.05% Ointment 50 gm Tube147.41USD tube
Diprolene AF 0.05% Cream 50 gm Tube147.02USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 45 gm Tube118.42USD tube
Diprolene 0.05% Gel 50 gm Tube103.99USD tube
Betamethasone Dipropionate Aug 0.05% Lotion 60ml Bottle100.64USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 50 gm Tube88.66USD tube
Betamethasone Dipropionate Aug 0.05% Gel 50 gm Tube88.26USD tube
Diprolene 0.05% Lotion 30ml Bottle78.79USD bottle
Betamethasone acetate powd78.03USD g
Diprolene 0.05% Ointment 15 gm Tube69.38USD tube
Diprolene AF 0.05% Cream 15 gm Tube69.38USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 15 gm Tube58.83USD tube
Betamethasone sod phos powder56.61USD g
Diprolene 0.05% Gel 15 gm Tube49.99USD tube
Betamethasone dp powder48.96USD g
Betamethasone valerate powd47.89USD g
Maxivate 0.05% Cream 45 gm Tube44.99USD tube
Betamethasone Dipropionate 0.05% Lotion 60ml Bottle40.4USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 15 gm Tube39.62USD tube
Betamethasone Dipropionate Aug 0.05% Gel 15 gm Tube39.46USD tube
Betamethasone Dipropionate 0.05% Ointment 45 gm Tube19.67USD tube
Betamethasone Dipropionate 0.05% Cream 45 gm Tube18.9USD tube
Betamethasone Valerate 0.1% Lotion 60ml Bottle16.99USD bottle
Betamethasone Valerate 0.1% Ointment 45 gm Tube15.87USD tube
Beta-Val 0.1% Lotion 60ml Bottle14.99USD bottle
Betamethasone Dipropionate 0.05% Ointment 15 gm Tube13.51USD tube
Betamethasone Dipropionate 0.05% Cream 15 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 45 gm Tube12.99USD tube
Beta-Val 0.1% Cream 45 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 15 gm Tube11.99USD tube
Betamethasone Valerate 0.1% Ointment 15 gm Tube11.99USD tube
Beta-Val 0.1% Cream 15 gm Tube11.99USD tube
Betnesol (5 mg/100Ml) 5 mg/enm Enema9.51USD enema
Celestone soluspan 6 mg/ml8.08USD ml
Betamethasone ac-sp 6 mg/ml vial7.68USD ml
Luxiq 0.12% foam5.01USD g
Diprolene af 0.05% cream4.19USD g
Lotrisone 1-0.05% Lotion2.89USD ml
Lotrisone cream2.71USD g
Betamethasone dp aug 0.05% crm2.17USD g
Diprolene Glycol 0.05 % Glycol Cream0.54USD g
Diprolene Glycol 0.05 % Glycol Ointment0.54USD g
Ratio-Topilene 0.05 % Glycol Cream0.54USD g
Ratio-Topilene 0.05 % Glycol Ointment0.54USD g
Diprolene Glycol 0.05 % Glycol Lotion0.49USD g
Ratio-Topilene 0.05 % Glycol Lotion0.49USD g
Prevex B 0.1 % Occlusive Cream0.4USD g
Beta-val 0.1% cream0.32USD g
Ratio-Ectosone Regular 0.1 % Lotion0.3USD g
Ratio-Ectosone Mild 0.05 % Lotion0.23USD g
Diprosone 0.05 % Ointment0.23USD g
Ratio-Topisone 0.05 % Ointment0.23USD g
Diprosone 0.05 % Cream0.21USD g
Diprosone 0.05 % Lotion0.21USD g
Ratio-Topisone 0.05 % Cream0.21USD g
Ratio-Topisone 0.05 % Lotion0.21USD g
Betamethasone va 0.1% cream0.14USD g
Betaderm Regular 0.1 % Ointment0.1USD g
Ratio-Ectosone Regular 0.1 % Cream0.1USD g
Valisone Scalp 0.1 % Lotion0.1USD g
Betaderm Regular 0.1 % Cream0.09USD g
Ratio-Ectosone Scalp 0.1 % Lotion0.09USD g
Betaderm Mild 0.05 % Ointment0.07USD g
Betaderm Mild 0.05 % Cream0.06USD g
Ratio-Ectosone Mild 0.05 % Cream0.06USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6126920No1996-03-012016-03-01Us
US7078058No1997-05-242017-05-24Us
US6753013No2000-01-272020-01-27Us
US6787529No2000-01-272020-01-27Us
US9119781No2011-06-102031-06-10Us
US9439911No2010-08-312030-08-31Us
US9433630No2010-08-312030-08-31Us
US9655907No2010-08-312030-08-31Us
US9364485No2010-08-312030-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)232 °CU.S. Patent 3,164,618
water solubility66.5 mg/L (at 25 °C)EPA
logP1.94HANSCH,C ET AL. (1995)
logS-3.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.88 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-0239000000-6da1b4bf9567b7486622
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05i4-2930000000-bc11f96b96bcca3051a8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3960000000-a7dc9d06200fd3114dc2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:3077)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035]
  2. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [PubMed:15336699]
  3. Johnstone JF, Bocking AD, Unlugedik E, Challis JR: The effects of chorioamnionitis and betamethasone on 11beta hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor in preterm human placenta. J Soc Gynecol Investig. 2005 May;12(4):238-45. [PubMed:15866114]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13